pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

4,945 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1852Endpoints1435Fierce Biotech751BioSpace741BioPharma Dive544raps245onclive165fda recalls118
therapy area
allOncology12805Rare Disease3303Immunology2978Cardiology2839Hematology2280Pulmonology2221Vaccines
  • John Powers III named permanent director of NIH's National Institute of Allergy and Infectious Diseases
    NIH's National Institute of Allergy and Infectious Diseases (NIAID) has finally filled its top leadership vacancy that has persisted since 2025. The institute had been led in an acting capacity by…
    STAT · 6h agoNeutral↗ source
  • CMS releases new AI roadmap; highlights from HLTH conference
    The latest STAT Health Tech newsletter reports that the Centers for Medicare & Medicaid Services (CMS) has published a new artificial intelligence (AI) roadmap outlining its approach to AI integrat…
    STAT · 2h agoRegulatoryNeutral↗ source
← prev
page 2 of 198
next →
fda medwatch113
globenewswire health73
fda press60
1837
Psychiatry & CNS1229
Ophthalmology1127
Endocrinology & Metabolism794
Pain787
Nephrology779
  • RFK Jr. urges federal funding for faith-based addiction recovery centers, sparking expert concerns over medication access
    Health Secretary Robert F. Kennedy Jr. toured Sheepgate, a Christian addiction recovery center in Iowa, and said the model should receive federal funding. He highlighted the center as an example of…
    STAT · 10h agoRegulatoryNeutral↗ source
  • Zero-tolerance signs in hospitals may not curb staff violence, authors argue
    Hospitals across the United States now display signs telling patients and visitors that abusive language, disruptive conduct, or aggression will not be tolerated and may result in removal or police…
    STAT · 10h agoNegative↗ source
  • Health tech firms eye consumer-driven future at HLTH conference in Las Vegas
    The Endpoints team attended the HLTH conference in Las Vegas despite a ground stop on Friday, gathering insights on health technology trends. Observations suggest the industry is shifting toward c…
    Endpoints · 3h agoNeutral↗ source
  • GSK’s Nuvalent buyout delivers again as FDA clears Nelkarmi for lung cancer
    GSK has secured a US accelerated approval for its oral lung cancer drug neladalkib, one of two assets at the heart of its $10.6 billion purchase of oncology drugmaker Nuvalent earlier this ...
    Endpoints · 14m ago↗ source
  • On eve of Senate committee vote, Trump's FDA pick hasn't locked up confirmation
    On Wednesday, the Trump administration's pick to lead the FDA will face a key vote in the Senate. Whether she'll pass or fail may go down to the wire. Less than 24 hours before the ...
    Endpoints · 15m ago↗ source
  • STAT+: Updated health data privacy rule sets standards for sharing records with apps
    Federal health department has updated the HIPAA privacy rule with a focus on supporting patients’ access to their own medical records.
    STAT · 20m ago↗ source
  • J&J to acquire Ollin Biosciences for $2.2 billion to advance bispecific eye drug OLN324 against Roche’s Vabysmo
    Johnson & Johnson announced it will buy Ollin Biosciences for an upfront $2.2 billion, with additional regulatory and commercial milestones that could bring total payments to about $3.3 billion. O…
    Fierce Biotech · 1d agoDealPositive↗ source
  • Eli Lilly inks up to $5.9 billion partnership with Stipple Bio to develop cancer therapies
    Eli Lilly announced a new collaboration with Cambridge-based biotech Stipple Bio, valued at up to $5.9 billion, aimed at creating novel cancer medicines. The agreement gives Lilly access to Stippl…
    Endpoints · 23h agoDealPositive↗ source
  • FDA approves Roche's Wilserdly for advanced HR-positive, HER2-negative breast cancer with ESR1 mutation
    The U.S. Food and Drug Administration has granted approval to Roche's new oral breast cancer therapy, Wilserdly (giredestrant). The decision clears the way for the drug's launch in the United State…
    STAT · 23h agoApprovalPositive↗ source
  • Helus Pharma reports Phase 3 depression trial shows symptom improvement but safety concerns linger
    Helus Pharma, a psychedelics-focused company, announced results of its Phase 3 trial for its lead depression drug. The trial showed the drug produced greater improvement in depression symptoms com…
    Endpoints · 1d agoPositive readoutNegative↗ source
  • CG Oncology’s cretostimogene cuts bladder cancer recurrence risk by 68% in Phase 3 trial
    CG Oncology reported that its experimental therapy, cretostimogene, achieved a 68% relative reduction in bladder cancer recurrence in a Phase 3 study of patients who had surgery for non‑muscle inva…
    BioPharma Dive · 1d agoPositive readoutPositive↗ source
  • Helus Pharma's modified psilocybin meets primary and secondary goals in phase 3 depression trial
    Helus Pharma reported that its oral, chemically modified psilocybin candidate, HLP003, was tested in a phase 3 study of 222 patients with major depressive disorder. Participants received a single 1…
    Fierce Biotech · 1d agoPositive readoutPositive↗ source
  • Eli Lilly acquires Calytrix Bio in $1.5 billion deal to add myelofibrosis antibody to its pipeline
    Eli Lilly announced a $1.5 billion acquisition of Massachusetts‑based Calytrix Bio, gaining access to the company’s biparatopic antibody aimed at mutant calreticulin‑driven essential thrombocythemi…
    Fierce Biotech · 1d agoDealPositive↗ source
  • Biogen signs $411 million deal with TrimTech to develop protein degraders for neurodegenerative diseases
    Biogen announced a collaboration with UK‑based TrimTech Therapeutics, valued at up to $411 million in biobucks, to create small‑molecule protein degraders aimed at neurodegenerative disorders. The…
    Fierce Biotech · 1d agoDealPositive↗ source
  • AriBio’s oral Alzheimer’s candidate shows significant benefit in monotherapy subgroup in phase 3 trial
    AriBio’s AR1001, an oral PDE5 inhibitor originally developed for erectile dysfunction, is being tested as a treatment for early Alzheimer’s disease. In the global phase 3 Polaris-AD trial, the dru…
    Fierce Biotech · 21h agoPositive readoutNeutral↗ source
  • Sellas vaccine shows 9-month overall survival gain in phase 3 AML trial
    Sellas Life Sciences reported results of a phase 3 trial of its peptide vaccine galinpepimut-S (GPS) in patients with acute myeloid leukemia (AML). The study met its primary endpoint, showing a me…
    Fierce Biotech · 1d agoPositive readoutPositive↗ source
  • FDA rejects Summit Therapeutics' ivonescimab combo, citing lack of survival benefit in lung cancer
    Summit Therapeutics and partner Akeso received a rejection from the U.S. Food and Drug Administration for their PD-1/VEGF antibody ivonescimab combined with chemotherapy. The agency said the data d…
    BioPharma Dive · 1d agoRegulatoryNegative↗ source
  • J&J to acquire Ollin Biosciences for up to $3.3 billion, adding eye disease drug to its portfolio
    Johnson & Johnson announced it will purchase Ollin Biosciences, a biotechnology startup developing an eye disease therapy. The transaction includes an upfront payment of $2.2 billion and up to $1.…
    BioPharma Dive · 1d agoDealPositive↗ source
  • Johnson & Johnson agrees to acquire eye-disease biotech Ollin Biosciences for up to $3.3 billion
    Johnson & Johnson announced Monday that it will purchase Ollin Biosciences, a biotech focused on eye diseases. The transaction is valued at up to $3.3 billion, representing one of the larger recen…
    Endpoints · 1d agoDealPositive↗ source
  • CG Oncology's bladder cancer immunotherapy cuts tumor recurrence risk by 68% in study
    CG Oncology reported that its bladder cancer immunotherapy, cretostimogene, achieved a 68% reduction in tumor recurrence compared with standard care. The treatment uses an engineered common cold v…
    STAT · 1d agoPositive readoutPositive↗ source
  • Eli Lilly to acquire Calytrix Bio for up to $1.5B, targeting rare blood cancers
    Eli Lilly announced it will acquire Calytrix Bio, a Massachusetts biotech, in a deal valued at up to $1.5 billion. Calytrix focuses on precision therapies for myeloproliferative neoplasms, includi…
    BioPharma Dive · 1d agoDealPositive↗ source
  • Flagship Pioneering invests £100 million to launch AI-focused biotech lab in London
    Flagship Pioneering, the life‑science investor behind Moderna, announced the creation of a new laboratory in London. The lab will concentrate on building AI‑native platform companies, using artifi…
    Endpoints · 1d agoDealPositive↗ source
  • CG Oncology reports 68% drop in bladder cancer recurrence in phase 3 trial of cretostimogene
    CG Oncology announced results from a phase 3 study of its oncolytic virus immunotherapy, cretostimogene, in patients with non-muscle invasive bladder cancer after surgery. The trial, involving 367…
    Fierce Biotech · 1d agoPositive readoutPositive↗ source